Overview

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This is a phase I, open-label clinical study of BioTTT001 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.

Phase:

PHASE1

Details

Lead Sponsor:

China Medical University, China

Collaborator:

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Treatments:

regorafenib
toripalimab